|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
EBSCO_ocn893206516 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
140829t20142014nyua ob 001 0 eng |
010 |
|
|
|a 2020688408
|
040 |
|
|
|a DLC
|b eng
|e rda
|e pn
|c DLC
|d OCLCF
|d D6H
|d AGLDB
|d VTS
|d STF
|d YDX
|d M8D
|d VLY
|d N$T
|d E7B
|d EBLCP
|d YDXCP
|d AU@
|d OCLCO
|d OCL
|d OCLCA
|d OCLCO
|d OCLCQ
|
019 |
|
|
|a 893673233
|a 904984451
|a 992841500
|
020 |
|
|
|a 9781604569667
|q (ebook)
|
020 |
|
|
|a 1604569662
|
020 |
|
|
|z 1633219615
|
020 |
|
|
|z 9781633219618
|
029 |
1 |
|
|a AU@
|b 000056024146
|
029 |
1 |
|
|a DEBBG
|b BV042795551
|
029 |
1 |
|
|a DEBBG
|b BV043783128
|
029 |
1 |
|
|a DEBSZ
|b 472849492
|
035 |
|
|
|a (OCoLC)893206516
|z (OCoLC)893673233
|z (OCoLC)904984451
|z (OCoLC)992841500
|
042 |
|
|
|a pcc
|
050 |
0 |
0 |
|a RB150.F37
|
060 |
|
4 |
|a WB 146
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
0 |
|a 616/.0478
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Chronic fatigue syndrome :
|b risk factors, management and impacts on daily life /
|c Connor Hudson, editor.
|
264 |
|
1 |
|a New York :
|b Nova Science Publishers, Incorporated,
|c [2014]
|
264 |
|
4 |
|c ©2014
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Neuroscience research progress
|
500 |
|
|
|a "Nova Biomedical."
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Print version record and cip data provided by publisher.
|
505 |
0 |
|
|a ""CHRONIC FATIGUE SYNDROME: RISK FACTORS, MANAGEMENT AND IMPACTS ON DAILY LIFE""; ""CHRONIC FATIGUE SYNDROME: RISK FACTORS, MANAGEMENT AND IMPACTS ON DAILY LIFE""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""Chapter I: The Internist�s View on Myalgic Encephalopathy and Complementary/Alternative Treatments""; ""Abstract""; ""Introduction""; ""Pathogenic Concept""; ""The Relation between Pathophysiology and the Clinic""; ""Therapeutic Options""; ""Clinical Experience""; ""Annex""; ""Conclusion and Future Prospects""; ""References""
|
505 |
8 |
|
|a Chapter II: Metal Hypersensitivity As the Cause of Chronic Fatigue Syndrome: Case ReportAbstract -- Introduction -- Conclusion -- References -- Chapter III: Illness Perception and Management in Chronic Fatigue Syndrome -- Abstract -- Introduction -- Illness Perception -- Illness Management -- Conclusion -- Acknowledgment -- References -- Chapter IV: A Review of Current Exercise Management Practices for Chronic Fatigue Syndrome -- Abstract -- 1. Introduction -- 2. Current Management and Treatments for CFS
|
505 |
8 |
|
|a 3. The Effects of Chronic Fatigue Syndrome on Exercise Responses4. Exercise Testing and Assessment for Chronic Fatigue Syndrome -- 5. Exercise Prescription and Programming for Chronic Fatigue Syndrome -- 6. Contraindications and Risks for Exercise and Physical Activity -- 7. Patient Needs and Clinical Practice Recommendations -- Conclusion -- References -- Chapter V: Management of Chronic Fatigue Syndrome: Current Approaches and Future Directions -- Abstract -- 1. Introduction -- 2. Proposed Management Strategies -- Conclusion -- References
|
505 |
8 |
|
|a Chapter VI: Innate Immune Changes in the Peripheral Blood of Chronic Fatigue Syndrome Patients: Risk Factors for Disease Progression and ManagementAbstract -- Introduction -- Profile of Circulating Leukocytes in SFFV Env Antibody Positive CFS Individuals -- SFFV Env Antibody Positive CFS Patients Have Lower Lymphocyte Percentages -- NKT Cells Are Markedly Increased and NK Cells, Particularly the CD56DIM Cells, Are SignificantlyReduced in SFFV Env Antibody Positive CfsPatients -- The Percentage of CD19+ B Cells Is Reduced inSFFV Env Antibody Positive CFS Patients
|
505 |
8 |
|
|a The Percentage of CD19+ B Cells Is Reduced inSFFV Env Antibody Positive CFS PatientsIncreased Activation of Myeloid Derived Cells inSFFV Env Antibody Positive CFS Patients -- Expression of CD69 on CD83+ CD86+ Cells inSFFV Env Antibody Positive CFS Patients IsAssociated with an Activated, Mature DendriticCell Compartment -- Cytokines and Chemokines Are Dysregulated inSFFV Env Antibody Positive Cfs Patients -- Additional Cytokine Signatures in SFFV EnvAntibody Positive CFS Patients Suggest AdditionalTargets and Benefits of Drug Repurposing
|
520 |
|
|
|a Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME) has no clear aetiology, and is defined as severe and chronic fatigue that has lasted for more than six consecutive months, which is not due to physical exertion or other medical conditions associated with fatigue. CFS patients may suffer from four or more of the following symptoms: post-exertional malaise lasting for more than 24 hours; tender or swollen lymph nodes; recurring sore throat; unrefreshing sleep; significantly impaired short-term memory and/or concentration; headaches; or joint pain. Management practices have include.
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Chronic fatigue syndrome.
|
650 |
|
0 |
|a Myalgic encephalomyelitis.
|
650 |
1 |
2 |
|a Fatigue Syndrome, Chronic
|
650 |
|
6 |
|a Fatigue chronique.
|
650 |
|
6 |
|a Encéphalomyélite myalgique.
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Myalgic encephalomyelitis.
|2 fast
|0 (OCoLC)fst01031274
|
650 |
|
7 |
|a Chronic fatigue syndrome.
|2 fast
|0 (OCoLC)fst00860107
|
700 |
1 |
|
|a Hudson, Connor,
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Chronic fatigue syndrome.
|d New York : Nova Science Publishers, Inc., [2014]
|z 1633219615
|w (DLC) 2014949878
|
830 |
|
0 |
|a Neuroscience research progress series.
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=863047
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL2097173
|
938 |
|
|
|a ebrary
|b EBRY
|n ebr10951472
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 863047
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 2848207
|
994 |
|
|
|a 92
|b IZTAP
|